Added advantage of daclatasvir drug not proved for persistent hepatitis C infection Data were lacking or unsuitable for research question The medication daclatasvir has been available since August 2014 for the treating adults with chronic hepatitis C infection drug information . The German Institute for Quality and Performance in HEALTHCARE examined in a dossier evaluation whether this new drug offers an added benefit over the appropriate comparator therapy. The medication producer presented data for sufferers without cirrhosis of the liver who are infected with hepatitis C virus genotype 1, and for patients with HCV genotype 4.
Synovial fluid examination is the most important investigation. Polyarticular conditions can present in the beginning with an individual inflamed joint. Contextual information and extra-articular features provide clues to the fundamental diagnosis often.. Acute monoarthritis: diagnosis in adults Recognition and appropriate management of an acute monoarthritis requires strategic assembly and evaluation of information from the history, the examination and some selective tests. Common factors behind monoarthritis are contamination, trauma and crystal-induced synovitis.